Back to Top

About

Kenneth Kinzler, Ph.D., is a molecular geneticist widely recognized for his role in helping to identify genetic mutations that initiate development of most colorectal cancers. As a co-director, with Bert Vogelstein, M.D., of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center, the duo created novel techniques for ana-lyzing gene expression and genetic errors in many human malignancies over the years. In the mid-1990s, he invented SAGE, Serial Analysis of Gene Expression, allowing analysis of gene expression in human cancers. He coined the term “transcrip-tome” to refer to genes that are transcribed at a particular point in time. He later invented digital PCD and other digital genomic approaches for the detection of trace levels of tumor DNA in blood and other tissues. The ability to measure DNA fragments shed by tumors in blood or other bodily fluids holds promise for finding early stage disease when a cancer can be prevent-ed, or even cured. In 2020, Dr. Kinzler reported in Science the results of a first-of-its-kind study of a liquid assay for circulating tumor in a general population of nearly 10,000 women with no evidence or history of cancer. This preliminary re-port showed that 26 unknown cancers were found but there were also many false positive results. Because of the potential for overdiagnosis, Drs. Kinzler and Vogelstein, with their team, have described the test as complementary, not a stand-alone measure of cancer’s presence. They continue to refine the assay with the goal of making a simple blood test for cancer detection a useful reality. Dr. Kinzler earned a Ph.D. in pharmacology and molecular sciences from Johns Hopkins University School of Medicine in 1988. He has received many awards, in-cluding a Merit Award and the Director’s Service Award from the National Cancer Institute, as well as recognition by the National Academy of Inventors for invent-ing the technology underlying digital biopsies. He is a long-time member of the NCI Early Detection Research Network.

View More >>

Skills

Experience

Professor of Medicine

Johns Hopkins University School of Medicine (JHUSM)

Jan-1990 to Present

Publication

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Background The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free...

  • dott image October, 2019

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Importance Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurren...

  • dott image March, 2018

Comparative lesion sequencing provides insights into tumor evolution

We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common. When combined with prior clini...

  • dott image January, 2018

Detection and localization of surgically resectable cancers with a multi-analyte blood test

Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid g...

  • dott image November, 2017

The Genomic Landscapes of Human Breast and Colorectal Cancers

Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalog the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breas...

  • dott image September, 2017

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future. Here we describe our efforts to develop a noninvasive blood test for the detection of pancreatic d...

Cancer-Associated Mutations in Endometriosis without Cancer

Background Endometriosis, defined as the presence of ectopic endometrial stroma and epithelium, affects approximately 10% of reproductive-age women and can cause pelvic pain and infertility...

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Stage II colon cancer, which has spread through the wall of the colon but has not metastasized to the lymph nodes, can present a therapeutic dilemma. On one hand, these tumors can usually be...

  • dott image August, 2015

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

Background Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA ...

Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas

To explore the potential of tumor-specific DNA as a biomarker for head and neck squamous cell carcinomas (HNSCC), we queried DNA from saliva or plasma of 93 HNSCC patients. We searched for s...